Khepri Animal Health develops a metabolic gene therapy platform to reverse cellular senescence and reduce chronic inflammation in animals. Their proprietary technology targets and clears senescent cells, addressing a key driver of tissue damage and disease progression.
Funding
Funding not disclosed
Founders
Product
Problem
Chronic inflammation and cellular senescence in animals contribute to disease progression and aging. The accumulation of senescent cells releases pro-inflammatory factors, leading to tissue damage and functional impairment.
Solution
Khepri Animal Health is developing a metabolic gene therapy platform designed to reverse cellular senescence and mitigate chronic inflammation in animals. Our proprietary technology targets and clears senescent cells, which are a primary driver of inflammation and tissue damage. By restoring normal cellular function, Khepri aims to address the underlying causes of chronic inflammatory diseases and improve animal health. This approach focuses on reconstituting cellular function and reducing persistent pro-inflammatory stimulation.
Target Audience
Khepri's primary customers are veterinary professionals and animal health organizations seeking advanced therapeutic solutions for chronic inflammatory conditions and age-related diseases in animals.
Features
- Metabolic gene therapy platform for targeting senescent cells.
- Proprietary technology for reversing cellular senescence.
- Mechanism to clear accumulated senescent cells.
- Reduction of pro-inflammatory factor release from senescent cells.
- Restoration of normal cellular function.